GIGA-564 

GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a K_d of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research^[1].

Human

GIGA-564 (0.001-100 μg/mL) exhibits extremely low activity in blocking the binding of CTLA-4 to CD80 and CD86 in ELISA assays^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GIGA-564 (5 mg/kg; i.p.; once every 3 days; 3 doses) induces a lower level of peripheral Treg proliferation than Ipilimumab (HY-P9901) in hCTLA-4 KI mice bearing MC38 tumors^[1].
GIGA-564 (0.3 mg/kg; i.p.; once every 3 days; 3 doses) exhibits excellent anti-tumor activity in hCTLA-4 KI mice bearing MC38 tumors^[1].
GIGA-564 (30 mg/kg; i.p.; once every 3 days; 9 doses) induces less toxicity than Ipilimumab (HY-P9901) in hCTLA-4 knock-in (KI) and hCTLA-4/hPD-1 double knock-in (KI) mice, as evidenced by lower liver enzyme levels, reduced colitis, and the absence of skin lesions at the tested dose^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1493  [NCBI]

P16410

CTLA4

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[GIGA-564]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Stone E L, et al. GIGA-564, a third generation anti-CTLA-4 with minimal ability to block CTLA-4 binding to B7 ligands, has enhanced efficacy but reduced toxicity compared to ipilimumab in pre-clinical models//JOURNAL FOR IMMUNOTHERAPY OF CANCER. BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND: BMJ PUBLISHING GROUP, 2022, 10: A1443-A1443.